New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1... Nov 07
European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (... Mar 03
New data showed positive effect of nintedanib on slowing decline of lung function in a broad range of fibrosing interstitial lung diseases with a progressive ... Oct 01
-Advertisements-